215results about "Lectin superfamily" patented technology

The invention is directed to oligonucleotides and oligonucleosides functionalized to include lipophilic moieties and having improved biostability and altered biodistribution in mammals. In one embodiment, such lipophilic oligonucleotide conjugates are used in a method of targeting antisense oligonucleotides to hepatic tissues and thereby preferentially modulating gene expression in the liver and associated tissues of a mammal.

The invention relates to chimeric antigen receptors (CAR), particularly relates to dual-signal independent chimeric antigen receptors (dsCAR), and also relates to immune response cells of the dual-signal independent chimeric antigen receptors (dsCAR) and uses of the immune response cells in preparation of drugs for treatment of malignant tumor and virus infected diseases. In detail, the dual-signal independent chimeric antigen receptors (dsCAR) can respectively identify two different family antigens of tumor cells and can respectively transmit two T-cell-activation related signals. One of the CAR can transmit a first T-cell-activation related signal by combing a ligand of a tumor specific antigen or a tumor-associated antigen to decide T-cell killing specificity, and the other CAR can transmit a second T-cell-activation related signal by combing a ligand of a membrane receptor (such as EGFR (epidermal growth factor receptor) family protein) widely expressed by the tumor cells to promote T cell activation, proliferation and survival. The dual-signal independent chimeric antigen receptors (dsCAR) can avoid the potential safety problems on the basis of maintaining curative effects of second generation and third generation CAR.

The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.

The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.

The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

The invention discloses a salmonella phage LPSE34. The preservation number of the salmonella phage LPSE34 is CCTCC NO 2018121. The phage is a broad-spectrum salmonella phage and can crack drug-tolerant salmonellas, it is identified that the phage belongs to myoviridae, and the phage is named as LPSE34. The phage LPSE34 is stable in titer at the pH of 4-12 and the temperature of 30-60 DEG C. The invention further discloses application of the salmonella phage in food, especially in chicken and ham systems; and in addition, the invention further discloses a compound edible coating film formed bytaking the phage as an antibacterial substance to be combined with sodium alginate, and compared with antibiotics and chemical preservatives, the phage cannot affect the texture and flavor of food andhas the characteristics of high specificity, no residue and safety. The salmonella phage LPSE34 can serve as a bacteriocidal substance/the antibacterial substance to control pollution of food-borne pathogens to the food and is a very promising biological agent for guaranteeing the food safety.

The invention relates to a double-specific chimeric antigen receptor T cell as well as a preparation method and application thereof. The double-specific chimeric antigen receptor double-specifically targeting human NKG2DL and human CD47 is constructed on the basis of human NKG2D and human SIRPalpha molecules as well as an immune response cell modified with the double-specific chimeric antigen receptor. The novel modified immune response cell can effectively realize targeting attack of multiple tumor cells, particularly positive tumor cells expressing NKG2DL and CD47 and can be used for preparing preparations for treating tumor. The preparation method of the immune response cell modified with the double-specific chimeric antigen receptor double-specifically targeting NKG2DL and CD47 comprises simple steps, the obtained immune response cell modified with the double-specific chimeric antigen receptor double-specifically targeting NKG2DL and CD47 has high specific killing rate for tumor cells.

The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.

Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.

The invention provides a novel recombined dual-function fusion protein and its preparation method and application. In the concrete, the fusion protein includes the following structure: membrane outer region of I type transmembrane protein and membrane outer region of II type transmembrane protein, both of which are series-connected via immunoglobulin. The dual-function protein can simultaneously block combination of two types of ligands and corresponding internal source receptors, to thereby suppress ligand biological activity. The invention also provides the function of a novel recombined dual-function fusion protein in disease treatment. The inventin can produce novel recombined dual-function fusion protein, via a gene engineering technique platform.

Disclosed are compositions comprising an Fc portion of IgE coupled to an agent. For example, disclosed are compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic. These compositions can be used as a vaccine or an immunotherapeutic. Thus, these compositions can modulate the immune system by both increasing and decreasing the immune response. The Fc portion of IgE can bind to CD23 and transport the antigen or immunotherapeutic across airway epithelial cells. Disclosed are methods of treating airway inflammation with compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic.

The object was to provide a method for distinguishing between species within the genus Staphylococcus; binding affinities between many types of lectins and bacteria belonging to the genus Staphylococcus were examined; and lectins of Tachylectin-2, LEL, KAA1, BCL11, CBA, HAA, HPA, STL, proBCA1, proBCA2, ULL, DSA, PWM, UDA, WFL, hypninA3, BCL11d, CFA1, CFA2, CLA, MPA1, MPA2, AC-avranin, algCSA, BML11b, BML11c, etc. were selected. Further, it was found that these lectins could be used to distinguish between species within the genus Staphylococcus.

The invention relates to the technical field of biological medicines, and in particular relates to an obtainment method of a C-type lectin and a derivative, an analogue or an active fragment thereof as well as applications of the C-type lectin and the derivative, the analogue or the active fragment thereof in mode detection of microorganisms and related molecules, induction of insects to generate antimicrobial peptides, preparation of an antibody of the C-type lectin and the derivative, the analogue or the active fragment thereof and the like. The amino acid sequence of the C-type lectin is shown as the figure 2-(A). The sequence of the derivative, the analogue or the active fragment of the C-type lectin is shown as the figure 3. The C-type lectin with an electrophoresis purity and even a HPLC (High Performance Liquid Chromatography) purity is obtained by performing ion-exchange chromatography or hydrophobic chromatography or affinity chromatography or gel filtration or salting or ultrafiltration separation and purification on the raw materials of the C-type lectin, or treating the raw materials of the C-type lectin through the combination of two or multiple methods among the ion-exchange chromatography, the hydrophobic chromatography, the affinity chromatography, the gel filtration, the salting or the ultrafiltration separation and purification and according to the recombination of the separation and purification methods.